Literature DB >> 16285001

Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus.

Luca Perabo1, Jan Endell, Susan King, Kerstin Lux, Daniela Goldnau, Michael Hallek, Hildegard Büning.   

Abstract

BACKGROUND: Viruses are being exploited as vectors to deliver therapeutic genetic information into target cells. The success of this approach will depend on the ability to overcome current limitations, especially in terms of safety and efficiency, through molecular engineering of the viral particles.
METHODS: Here we show that in vitro directed evolution can be successfully performed to randomize the viral capsid by error prone PCR and to obtain mutants with improved phenotype.
RESULTS: To demonstrate the potential of this technology we selected several adeno-associated virus (AAV) capsid variants that are less efficiently neutralized by human antibodies. These mutations can be used to generate novel vectors for the treatment of patients with pre-existing immunity to AAV.
CONCLUSIONS: Our results demonstrate that combinatorial engineering overcomes the limitations of rational design approaches posed by incomplete understanding of the infectious process and at the same time offers a powerful tool to dissect basic viral biology by reverse genetics. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16285001     DOI: 10.1002/jgm.849

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  50 in total

Review 1.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

Review 2.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

3.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 4.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 5.  Matrices and scaffolds for DNA delivery in tissue engineering.

Authors:  Laura De Laporte; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2007-04-14       Impact factor: 15.470

Review 6.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

7.  A NEW RECOMBINANT ADENO-ASSOCIATED VIRUS (AAV)-BASED RANDOM PEPTIDE DISPLAY LIBRARY SYSTEM: INFECTION-DEFECTIVE AAV1.9-3 AS A NOVEL DETARGETED PLATFORM FOR VECTOR EVOLUTION.

Authors:  Kei Adachi; Hiroyuki Nakai
Journal:  Gene Ther Regul       Date:  2010-10

Review 8.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

9.  Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.

Authors:  Wuping Li; Liqun Zhang; Jarrod S Johnson; Wu Zhijian; Joshua C Grieger; Xiao Ping-Jie; Lauren M Drouin; Mavis Agbandje-McKenna; Raymond J Pickles; R Jude Samulski
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

Review 10.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.